Jean-Christophe Corvol1,2,3,4, Werner Poewe5. 1. Sorbonne Universités UPMC Univ Paris 06 UMR_S1127 ICM Paris France. 2. INSERM UMR_S1127 and CIC-1422 ICM Paris France. 3. CNRS UMR_7225 ICM Paris France. 4. Département des maladies du système nerveux AP-HP Hôpital Pitié-Salpêtrière Paris France. 5. Department of Neurology Medical University Innsbruck Innsbruck Austria.
Abstract
BACKGROUND: Pharmacogenetics aims to identify the genetic factors participating in the heterogeneity of drug response. The ultimate goal is to provide personalized treatment by identifying responders and non-responders, individuals at risk of developing drug adverse effects, and by adjusting dosage. Several studies have been performed in Parkinson's disease (PD), to investigate drug response variability according to genetic factors for dopamine replacement therapies. METHODS: We performed a systematic literature search of articles related to pharmacogenetic studies in PD, and found 47 studies. FINDINGS: Motor response and adverse reactions to dopaminergic drugs were associated with genes encoding enzymes of their metabolism as well as their receptors or targets. Despite some interesting results, considerable work remains to be done to replicate and validate their clinical relevance before translation into clinical practice. CONCLUSIONS: There are currently no guidelines published for pharmacogenetic factors related to PD drugs. More research is need in this field in order to improve our knowledge in drug response variability in PD. Algorithms taking into account clinical, pharmacological, and genetic factors are probably the most promising way to help for a personalized medicine in PD.
BACKGROUND: Pharmacogenetics aims to identify the genetic factors participating in the heterogeneity of drug response. The ultimate goal is to provide personalized treatment by identifying responders and non-responders, individuals at risk of developing drug adverse effects, and by adjusting dosage. Several studies have been performed in Parkinson's disease (PD), to investigate drug response variability according to genetic factors for dopamine replacement therapies. METHODS: We performed a systematic literature search of articles related to pharmacogenetic studies in PD, and found 47 studies. FINDINGS: Motor response and adverse reactions to dopaminergic drugs were associated with genes encoding enzymes of their metabolism as well as their receptors or targets. Despite some interesting results, considerable work remains to be done to replicate and validate their clinical relevance before translation into clinical practice. CONCLUSIONS: There are currently no guidelines published for pharmacogenetic factors related to PD drugs. More research is need in this field in order to improve our knowledge in drug response variability in PD. Algorithms taking into account clinical, pharmacological, and genetic factors are probably the most promising way to help for a personalized medicine in PD.
Entities:
Keywords:
Parkinson's disease; dopamine agonists; drug response; levodopa; pharmacogenetics
Authors: Ida Rissling; Yvonne Körner; Frank Geller; Karin Stiasny-Kolster; Wolfgang H Oertel; J Carsten Möller Journal: Sleep Date: 2005-07 Impact factor: 5.849
Authors: Maurits E L Arbouw; Kris L L Movig; Toine C G Egberts; Petra J E Poels; Jeroen P P van Vugt; Judith A M Wessels; R J H M van der Straaten; Cees Neef; Henk-Jan Guchelaar Journal: Eur J Clin Pharmacol Date: 2009-12 Impact factor: 2.953
Authors: Cynthia D J Kusters; Kimberly C Paul; Aline Duarte Folle; Adrienne M Keener; Jeff M Bronstein; Valerija Dobricic; Ole-Bjørn Tysnes; Lars Bertram; Guido Alves; Janet S Sinsheimer; Christina M Lill; Jodi Maple-Grødem; Beate R Ritz Journal: Neurol Genet Date: 2020-07-20